TCT Late-Breaking Debut: China's Homegrown World’s Smallest VAD NyokAssist® Challenges New Standards in High-Risk PCI
magAssist
Developer of Extracorporeal Artificial Heart Devices
TCT Late-Breaking Clinical Session to Be Released Soon:
Clinical Outcomes of the World's Smallest Chinese-Developed VAD "NyokAssist®" Set to Revolutionize Global High-Risk PCI Treatment Standards
Late-Breaking Session
NyokAssist®
Global LaunchMulticenter Randomized Controlled Clinical Outcomes
This release focuses on "SAVE-PCI”
A study in high-riskPCIAmong patients, a smaller-diameter percutaneous ventricular assist device (pVAD) and Intra-Aortic Balloon Pump (IABP) Prospective randomized controlled study on supportive effectsClinicalTest
The study was conducted byProf. Ge Junbo, Academician of Fudan University Zhongshan HospitalLed by multiple well-known clinical teams in China, for the current clinical mostChallenging high-risk PCI scenarios,System Evaluation of the Application Value of a Novel Interventional Ventricular Assist Device。
This is one of the first systematic evaluations globallySmall size, foldableVADA prospective large-scale randomized controlled study on the IABP support strategy, and it is also the first time that China's original pVAD technology has been selected for the TCT Late-Breaking Clinical Science session.
Three TCT Keywords
Define this milestone release
Pioneering Research—— China's Originals Enter the Global Core Clinical Research Stage
Groundbreaking Discovery—— The First Prospective Clinical Evidence of Head-to-Head Comparison Between Small-Size VAD and IABP
Unmatched Impact—— Attracting widespread attention from top international clinical experts
TCT selects only a very small number of studies from global submissions each year for the Late-Breaking Clinical Science session, representingThe Highest Academic Recognition and International Communication Value。NyokAssist® is so farVery few projects featuring medical devices independently developed in China have been selected., which is of great international academic and industrial significance.
The Least Challenge, To Overcome the Hardest
NyokAssist® Synchronized Release of Real Clinical Cases
NyokAssist®9Fr Maximum Outer DiameterAchieving a structural breakthrough, yet facing the most complex and highest-risk clinical scenarios.
In addition to the complete randomized controlled trial data, the research team will also be present at TCT.Showcasing Forward-Looking Animal Experiments and Multiple Real-World Challenging Cases。
This will not only be a demonstration of product capabilities, but also a targeted approach againstThe Most Challenging Systemic Response to Treatment。
For detailed cases and schedule, please see the image at the end of the article orAttachment PDF
Special Invitation
magAssist Booth 2330 · Discussing the Future
During TCT 2025, magAssist will be inBooth #2330Showcase NyokAssist® Technology Platform and Research Achievements, Sincerely Invite Global Cardiovascular Experts, Partners, and Peers to Visit and Exchange.
The event will also feature device demonstrations, case presentations, and face-to-face interactions with the research team, providing an in-depth interpretation of clinical usage experiences and technical details.
Not Just an International Debut
It is still the beginning of the globalization journey.
NyokAssist® is addressing global treatment challenges with rigorous clinical data, promoting the establishment of a credible voice for China's original medical technology in the international academic community.
We will not only bring original data from China but also soon launch formal clinical trials in the United States, moving towards the global multi-center research phase.
We look forward to meeting you at TCT 2025 to witness the innovative power of China for global high-risk...PCINew Solutions Brought by Treatment, Exploring the Future Direction of Mechanical Circulatory Support Together.
Schedule Overview as Follows
- END -
